Experimental vaccine trains immune system to fight multiple cancers
NCT ID NCT01147965
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a cancer vaccine called ETBX-011 in 43 people with advanced colorectal, lung, breast, or prostate cancers that produce a protein called CEA. The vaccine uses a modified virus to teach the immune system to attack cancer cells making CEA. The main goals were to check safety and see if the vaccine triggers an immune response against the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ad5 [E1-, E2b-]-CEA(6D) vector vaccine (ETBX-011)
What this could lead to
If successful, this vaccine could help the immune system recognize and attack cancer cells that produce CEA, potentially slowing tumor growth or shrinking tumors in advanced cancers.
What could go wrong
This is an early-phase trial with only 43 participants, so the vaccine may not prove effective or safe in larger groups. It is designed for advanced cancers, so benefits may be limited and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Research Institute, Duke University
Durham, North Carolina, 27710, United States
-
Medical Oncology Associates, PS
Spokane, Washington, 99208, United States